Piper Sandler lowered the firm’s price target on Pliant Therapeutics (PLRX) to $17 from $40 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial of bexotegrast
- Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Cheat Sheet
- Positive Outlook on Pliant Therapeutics Despite Trial Uncertainty
- Hold Rating on Pliant Therapeutics Amid Safety Concerns in BEACON-IPF Trial
- Optimistic Buy Recommendation Amid Pliant Therapeutics’ Trial Review and Stock Surge